Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie for å teste forskjellige doser av BI 1584862 hos personer med en distinkt form for aldersrelatert makuladegenerasjon (AMD) kalt geografisk atrofi

29. september 2026 oppdatert av: Boehringer Ingelheim

JADE: Fase II-studie i pasienter med geografisk atrofi: En randomisert, dobbeltmasket, placebokontrollert, dosefinnende studie for å evaluere effektiviteten og sikkerheten til BI 1584862

This study is open to adults aged 50 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study is to find out whether a medicine called BI 1584862 improves the eyes in people with geographic atrophy and to find the most suitable dose.

This study has 4 treatment groups. Participants are put into groups randomly, which means by chance. Initially participants can join a BI 1584862 and a placebo group; then more participants are put randomly in 2 additional BI 1584862 groups and a placebo group.

Participants are in the study for 1 year. During this time, they visit the study site 13 times. At the visits, doctors check the severity of participants' eye disease and collect information on any health problems. They take detailed pictures of the back of the eye, the retina, with imaging methods called fundus autofluorescence (FAF), near-infrared reflectance (NIR), and optical coherence tomography (OCT). They measure areas of the retina that appear healthy (bright) or start to waste away (dark, atrophy). The changes over time are then compared between the treatment groups.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Studietype

Intervensjonell

Registrering (Faktiske)

150

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Arizona
      • Gilbert, Arizona, Forente stater, 85297
        • Associated Retina Consultants
      • Phoenix, Arizona, Forente stater, 85020
        • Associated Retina Consultants, Ltd.
      • Phoenix, Arizona, Forente stater, 85050
        • Cameron Ria, LLC
      • Scottsdale, Arizona, Forente stater, 85255
        • Retina Macula Institute of Arizona
    • California
      • Beverly Hills, California, Forente stater, 90211
        • Retina-Vitreous Associates Medical Group
      • Glendale, California, Forente stater, 91204
        • Global Research Management
      • Huntington Beach, California, Forente stater, 92647
        • Retina Associates of Southern California
      • Modesto, California, Forente stater, 95356
        • Retinal Consultants Medical Group, Inc
      • Mountain View, California, Forente stater, 94040
        • Northern California Retina Vitreous Associates MedicalGroup, Inc.
      • Newport Beach, California, Forente stater, 92663
        • Eye Research Foundation
      • Poway, California, Forente stater, 92064
        • Retina Consultants of San Diego
      • Sacramento, California, Forente stater, 95825
        • Retinal Consultants Medical Group
      • Walnut Creek, California, Forente stater, 94598
        • Bay Area Retina Associates - Walnut Creek
    • Colorado
      • Denver, Colorado, Forente stater, 80222
        • Retina Specialists of Colorado Research, LLC
    • Connecticut
      • Greenwich, Connecticut, Forente stater, 06830
        • Coastal Eye Surgeons
    • Florida
      • Gainesville, Florida, Forente stater, 32605
        • Vitreo Retinal Associates - Gainesville
      • Miami, Florida, Forente stater, 33143
        • MedEye Associates
      • Pinellas Park, Florida, Forente stater, 33782
        • Eye Associates of Pinellas
      • Stuart, Florida, Forente stater, 34994
        • East Florida Eye Institute
      • Winter Haven, Florida, Forente stater, 33880
        • Center for Retina and Macular Disease
    • Georgia
      • Augusta, Georgia, Forente stater, 30909
        • Southeast Retina Center, PC
    • Illinois
      • Oak Park, Illinois, Forente stater, 60304
        • Illinois Retina Associates - Oak Park
    • Kentucky
      • Louisville, Kentucky, Forente stater, 40206
        • The Eye Care Institute
    • Maryland
      • Hagerstown, Maryland, Forente stater, 21740
        • Cumberland Valley Retina Consultants
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02114
        • Ophthalmic Consultants of Boston
    • Missouri
      • Columbia, Missouri, Forente stater, 65212
        • University of Missouri Health System
    • New Jersey
      • Teaneck, New Jersey, Forente stater, 07666
        • NJRetina
    • Oregon
      • Eugene, Oregon, Forente stater, 97401
        • Verum Research, LLC
      • Portland, Oregon, Forente stater, 97221
        • Retina Northwest
      • Portland, Oregon, Forente stater, 97225
        • EyeHealth Northwest
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19107
        • Mid Atlantic Retina - Wills Eye Hospital
    • South Carolina
      • Charleston, South Carolina, Forente stater, 29414
        • Charleston Neuroscience Institute - Charleston
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37203
        • Tennessee Retina
    • Texas
      • Austin, Texas, Forente stater, 78750
        • Austin Clinical Research, LLC
      • Beaumont, Texas, Forente stater, 77707
        • Retina Consultants of Texas - Beaumont
      • Dallas, Texas, Forente stater, 75231
        • Retina Foundation of the Southwest
      • Plano, Texas, Forente stater, 75024
        • Red River Research Partners, LLC - Plano
      • San Antonio, Texas, Forente stater, 78240
        • Retinal Consultants of San Antonio
      • Schertz, Texas, Forente stater, 78154
        • Retina Consultants of Texas - Schertz
      • The Woodlands, Texas, Forente stater, 77384
        • Retina Consultants of Texas-The Woodlands-67575
    • Virginia
      • Falls Church, Virginia, Forente stater, 22042
        • Emerson Clinical Research Institute
      • Lynchburg, Virginia, Forente stater, 24502
        • Piedmont Eye Center
    • Washington
      • Bellevue, Washington, Forente stater, 98004
        • Pacific Northwest Retina
      • Arecibo, Puerto Rico, 00612
        • Emanuelli Research & Development Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

50 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion criteria:

  • Men and women with at least 1 eye with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) determined by fundus autofluorescence (FAF). The total size of all GA lesions in the study eye (as determined by the independent central reading center (CRC)) must be ≥1.25 mm^2 and ≤12.0 mm^2:

    • If multiple lesions are present in the study eye, at least 1 lesion must have an area of ≥0.5 mm^2
    • At least 1 GA lesion must be at least in part within a 1500 μm radius ring centered on the fovea
    • The foveal center point must not be involved in any atrophic lesion
    • Lesion(s) must reside completely within the FAF image
  • Best corrected visual acuity (BCVA) score of ≥50 letters in the study eye using the early treatment diabetic retinopathy study (ETDRS) chart (approximately equivalent to ≥20/100 on the Snellen chart).

  • Hyperautofluorescence of any pattern, as assessed by the CRC, must be present in the junctional zone of GA in the study eye.

  • Age ≥50 years.

  • Men must be willing and able to use contraception (condom, abstinence) to prevent pregnancy and/or exposure of an existing embryo or fetus to the investigational product. A female participant is eligible if she is not a woman of childbearing potential.

  • Signed informed consent consistent with International Conference of Harmonization-Good Clinical Practice (ICH GCP) guidelines and local legislation

Exclusion criteria:

  • Any history of, or evidence of, exudative age-related macular degeneration (eAMD) in the study eye.

  • Previously received treatment for GA in the study eye within 4 months or 5 half-lives, prior to baseline, whichever is longer.

  • Previously received an investigational medication (oral or intravitreal) for GA within 4 months or 5 half-lives prior to baseline, whichever is longer.

  • Additional eye disease in the study eye that could compromise BCVA or significantly impact retinal morphology:

    • uncontrolled glaucoma, defined as a disk-to-cup ratio >0.8 or ocular hypertension with intra ocular pressure (IOP) >24 mmHg at screening visit, or use of >2 active IOP-lowering agents in the study eye
    • clinically significant diabetic retinopathy or maculopathy in the opinion of the investigator
    • history of high myopia, i.e. spherical equivalent of ≥8 diopters or axial length ≥27.2 mm. Note: if subject had prior cataract or refractive surgery, spherical equivalent should be evaluated with pre-operative refraction. If axial length measurement is not available in medical records and cannot be obtained at screening visit, assessment of high myopia can be made by investigator on clinical examination.
    • anterior segment and vitreous abnormalities that would preclude adequate observation with SD-OCT in the opinion of the investigator
    • other ocular conditions at the discretion of the investigator that might interfere with the outcome of the trial
  • Significant disease or other medical conditions (as determined by medical history, examination, and clinical investigations at screening) that may, in the opinion of the investigator result in any of the following:

    • put the participant at risk because of participation in the study
    • influence the results of the study
    • cause concern regarding the participant's ability to comply with the protocol requirements or complete the trial as scheduled (e.g. chronic alcohol or drug abuse or any other condition that, in the investigator's opinion, makes the participant an unreliable trial participant)
  • Known hypersensitivity to any of the ingredients used in the investigational medicinal product (IMP) formulation, or any of the medications used.

  • Active intraocular inflammation in the study eye.

  • Active infectious conjunctivitis in either eye. Further exclusion criteria apply.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: Placebo-matchende BI 1584862

Placebo-matching BI 1584862

Eksperimentell: BI 1584862 dose 1

BI 1584862

Eksperimentell: BI 1584862 dose 2

BI 1584862

Eksperimentell: BI 1584862 dose 3

BI 1584862

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Slope of change from baseline in square root transformed geographic atrophy (GA) area as measured by fundus autofluorescence (FAF) over a treatment period of up to 50 weeks (expressed in mm/year) in the study eye
Tidsramme: Up to week 50.

mm is millimeters.

Up to week 50.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Forekomst av TEAES fra legemiddeladministrasjon til uke 52
Tidsramme: Inntil uke 52.
Inntil uke 52.
Endring fra baseline i delvis dempning som en prosentandel av ellipsoidsonen (EZ) ved makulaområdet med tykkelse <20 mikrogram (μm) opp til uke 50 vurdert ved volumetrisk optisk koherenstomografi (OCT) i studieøyet
Tidsramme: Inntil uke 50.
Inntil uke 50.
Endring fra baseline i kvadratrot transformert geografisk atrofi (GA) område målt ved fundus autofluorescens (FAF) ved uke 50 (uttrykt i mm) i studieøyet
Tidsramme: Ved baseline og ved uke 50.
Ved baseline og ved uke 50.
Key secondary endpoint: Change from baseline in total attenuation as a percentage of the EZ at the macular area with a thickness of 0 μm up to week 50 assessed by volumetric OCT and EZ mapping in the study eye
Tidsramme: Up to week 50.

EZ stands for ellipsoid zone. OCT stands for optical coherence tomography.

Up to week 50.
Key secondary endpoint: Slope of change from baseline in square root transformed GA area as measured by OCT over a trial period of up to 50 weeks (expressed in mm/year) in the study eye
Tidsramme: Up to week 50.

GA stands for geographic atrophy. OCT stands for optical coherence tomography. mm is millimeters.

Up to week 50.
Occurrence of BCVA letter loss of ≥15 from baseline in the study eye as measured by standardized ETDRS chart for at least 2 consecutive visits between baseline and up to Week 50
Tidsramme: Up to week 50.

ETDRS is early treatment diabetic retinopathy study.

Up to week 50.
Change from baseline in best-corrected low luminance visual deficit (LLVD) score as measured in letters by ETDRS chart under low-luminance conditions at Week 50 in the study eye
Tidsramme: At baseline and at week 50.

ETDRS is early treatment diabetic retinopathy study.

At baseline and at week 50.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Hjelpsomme linker

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

31. januar 2025

Primær fullføring (Antatt)

22. desember 2026

Studiet fullført (Antatt)

5. januar 2027

Datoer for studieregistrering

Først innsendt

7. januar 2025

Først innsendt som oppfylte QC-kriteriene

7. januar 2025

Først lagt ut (Faktiske)

10. januar 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

30. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

29. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 1484-0005
  • U1111-1309-9115 (Registeridentifikator: WHO International Clinical Trials Registry Platform (ICTRP))

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement".

Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

IPD-delingstidsramme

One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Tilgangskriterier for IPD-deling

For study documents - upon signing of a 'Document Sharing Agreement'.

For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere